ArticleMovement disorders clinical practice2025
Longitudinal Study of Treatment Variability for Parkinson's Disease across Specialized Centers.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insights and Unresolved Questions on Treatment Variability in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).BMJ neurology open · 2026Article
- Addressing Variability and Bridging the Gap in Parkinson's Disease Care: A Call to Action.Movement disorders clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundReal-world evidence on treatment practices in Parkinson's disease (PD) has been limited due to the difficulty in collecting comprehensive and generalizable clinical data.
objectivesWe sought to identify treatment patterns and test how treatment changed in response to (1) falling, (2) worsening disease, and (3) worsening quality of life across PD specialized centers.
methodsWe used the Parkinson Outcomes Project data collected from 2010 to 2023 across 31 international PD specialized centers. Demographic and clinical characteristics were collected annually and included medication use, physical therapy referral, psychologist or psychiatrist care, and deep brain stimulation (DBS) surgery. Treatment practice variation was described by center and in response to outcomes (self-reported falls, higher Hoehn and Yahr stage, worse emotional and mobility subscale scores on quality-of-life scale).
resultsA total of 12,664 participants were analyzed. Treatment practices varied substantially across centers with the use of levodopa in the first 5 years of disease ranging from 59.3% to 94.6% and physical therapy referral ranging from 13% to 71%. At ≥ 5 years of disease, DBS rates varied from 2% to 41%. After a fall, individuals were more likely to be referred for physical therapy (β: 0.44, 95% confidence interval [CI]: 0.36, 0.52), and mental health services were recommended after a decline in emotional subscores (β: 1.74, 95% CI: 1.50, 1.98). However, there was no change in levodopa-equivalent daily dose after worsening mobility subscores (β: -29.97, 95% CI: -76.67, 16.73).
conclusionsThese results highlight the large variability in PD practice across specialty centers and the importance of establishing best practice guidelines. Understanding the drivers of this variability is an essential next step.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.